Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus. In the current trial this effect of linagliptin treatment on endothelial function will be compared against both the sulfonylurea glimepiride and against placebo, which has not been tested in a trial before; as also is the case for other DPP-4 inhibitors.

Besides placebo, glimepiride was chosen as a comparator, as it is one compound of the second most used oral antidiabetic drug class.

Condition or disease	Intervention/treatment	Phase
Diabetes Mellitus, Type 2	Drug: Placebo; Drug: Linagliptin; Drug: Glimepiride	Phase 1

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	42 participants
Allocation:	Randomized
Intervention Model:	Crossover Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')
Study Start Date :	October 2012
Actual Primary Completion Date :	January 2014
Actual Study Completion Date :	January 2014

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Linagliptin 5mg; given once daily over 28 days	Drug: Placebo; Placebo matching Glimepiride Drug: Linagliptin; given once daily for 28 days
Active Comparator: Glimepiride; given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days	Drug: Placebo; Placebo matching Linagliptin Drug: Glimepiride; 1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
Placebo Comparator: Placebo; given once daily over 28 days	Drug: Placebo; Placebo matching Linagliptin Drug: Placebo; Placebo matching Glimepiride

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28 [ Time Frame: baseline and day 28 for each treatment arm ]
   Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.

Secondary Outcome Measures :

1. Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28 [ Time Frame: baseline and day 28 for each treatment arm ]
   Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
2. Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28 [ Time Frame: baseline and day 28 for each treatment arm ]
   Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
3. Number of Patients With Adverse Events [ Time Frame: up to 20 weeks ]
   Number of patients with any adverse events

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

1. Type 2 diabetic male and female patients according to the following criteria:

   Based upon a complete medical history and clinical laboratory tests

2. Age >= 18 and Age <= 65 years
3. Body mass index >= 25 <= 35 kg/m2
4. HbA1c <= 7.5%
5. Treatment with metformin (=1500 mg daily) for <= 3 months

6. Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.

   For female patients of childbearing potential:

7. Use of acceptable method of contraception (Pearl-Index <1).

Exclusion criteria:

1. Treatment with any glucose-lowering drug except for metformin within prior 3 months.
2. Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance.
3. Any evidence of a clinically relevant acute concomitant disease
4. History of cardiovascular disease (e.g. coronary artery disease history of acute myocard infarction or stroke, peripheral vascular disease).
5. History of major diabetic complications (e.g. nephropathy, retinopathy)
6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, immunological or hormonal disorders (except: hypertension treated with angiotensin receptor blocker or angiotensin-converting-enzyme inhibitors, hyperlipidemia with statin therapy, thyroid hormone replacement therapy, all stable for at least three months prior to screening).
7. Surgery of the gastrointestinal tract (except appendectomy).
8. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
9. History of relevant orthostatic hypotension, fainting spells or blackouts.
10. Chronic or relevant acute infections.
11. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients).
12. Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial.
13. Participation in another trial with an investigational drug within one month prior to administration or during the trial.
14. Smoker (>= 1 cigarettes or >= 1 cigars or >= 1 pipes/day).
15. Alcohol abuse (more than 60 g/day).
16. Drug abuse.
17. Blood donation (more than 100 mL within four weeks prior to administration or during the trial).
18. Excessive physical activities (within one week prior to administration or during the trial).
19. Any laboratory value outside the reference range that is of clinical relevance.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

Germany
1218.105.001 Boehringer Ingelheim Investigational Site
Neuss, Germany

Sponsors and Collaborators

Boehringer Ingelheim

Eli Lilly and Company

Investigators

Study Chair:	Boehringer Ingelheim	Boehringer Ingelheim

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

Related Info 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol. 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3.

Responsible Party:	Boehringer Ingelheim
ClinicalTrials.gov Identifier:	NCT01703286 History of Changes
Other Study ID Numbers:	1218.105; 2012-003317-33 ( EudraCT Number: EudraCT )
First Posted:	October 10, 2012
Results First Posted:	January 19, 2015
Last Update Posted:	January 19, 2015
Last Verified:	January 2015

Additional relevant MeSH terms:

Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Glimepiride; Linagliptin; Anti-Arrhythmia Agents; Hypoglycemic Agents; Physiological Effects of Drugs	Immunosuppressive Agents; Immunologic Factors; Incretins; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Dipeptidyl-Peptidase IV Inhibitors; Protease Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action